207 related articles for article (PubMed ID: 17257452)
1. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold DT; Safi W; Trinh H
Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
[TBL] [Abstract][Full Text] [Related]
2. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
Gold DT; Trinh H; Safi W
Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
[TBL] [Abstract][Full Text] [Related]
3. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
4. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Binkley N; Martens MG; Silverman SL; Derman RJ; Greenwald M; Kohles JD; Bachmann GA
South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
[TBL] [Abstract][Full Text] [Related]
5. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Keen R; Jodar E; Iolascon G; Kruse HP; Varbanov A; Mann B; Gold DT
Curr Med Res Opin; 2006 Dec; 22(12):2375-81. PubMed ID: 17257451
[TBL] [Abstract][Full Text] [Related]
6. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Chung YS; Lim SK; Chung HY; Lee IK; Park IH; Kim GS; Min YK; Kang MI; Chung DJ; Kim YK; Choi WH; Shong MH; Park JH; Byun DW; Yoon HK; Shin CS; Lee YS; Kwon NH
Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
8. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
10. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
[TBL] [Abstract][Full Text] [Related]
11. Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
Moro-Alvarez MJ; Díaz-Curiel M
Clin Interv Aging; 2008; 3(2):227-32. PubMed ID: 18686745
[TBL] [Abstract][Full Text] [Related]
12. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
Emkey R; Koltun W; Beusterien K; Seidman L; Kivitz A; Devas V; Masanauskaite D
Curr Med Res Opin; 2005 Dec; 21(12):1895-903. PubMed ID: 16368038
[TBL] [Abstract][Full Text] [Related]
13. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
[TBL] [Abstract][Full Text] [Related]
14. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
15. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
[TBL] [Abstract][Full Text] [Related]
16. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
[TBL] [Abstract][Full Text] [Related]
18. Once-monthly dosing: an effective step forward.
Reid DM
Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
[TBL] [Abstract][Full Text] [Related]
19. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Okazaki R
Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]